Therefore, we hypothesized that the addition of recombinant SRCR1-4 to PAMs would interfere with PRRSV internalization and sequential infection via competitive inhibition for MYH9 binding and thus would interrupt the endogenous CD163 and MYH9 interaction. This evidence concerns the gene MYH9 and infection.